In a nutshell
This study investigated the outcomes of hemodialysis in patients with multiple myeloma. The main finding was that those who did not undergo hemodialysis had better survival than those who did.
Multiple myeloma (MM) is a type of cancer which affects the white blood cells which produce antibodies (proteins that fight infection). Kidney disease commonly affects patients with MM. It results in the kidneys not being able to remove waste products from the blood properly. On average, about 40% of patients with MM develop Myeloma-associated kidney disease (MRKD). Common treatment for MRKD is hemodialysis. This involves clearing the blood of any waste products that the kidney normal would remove. It is important to research the effect of hemodialysis in patients with MM.
Methods & findings
One thousand, six hundred and ten patients with MM were included in this study. These patients were monitored between 2000 and 2010. Development of MRKD was monitored in these patients.
It was found that individuals with MM were more likely to undergo hemodialysis than those without. Patients who had hemodialysis within the 1st year following MM diagnosis were less likely to survive. Almost 62% of patients had hemodialysis in the 1st year after being diagnosed. Patients who underwent less hemodialysis in the first year had better survival. If patients recovered following hemodialysis they were more likely to respond.
The bottom line
The main finding was that patients with MM who did not undergo hemodialysis had better survival than those who did.
The fine print
This study only included patients from Taiwan. Therefore the results may not apply to patients from elsewhere.
If you have questions about MM, please consult your doctor.
Published By :
Aug 01, 2018
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?